Gilead Terminates Cicletanine Trial; All Eyes Remain on Quad
Gilead Sciences Inc., of Foster City, Calif., has terminated a Phase II trial of cicletanine for pulmonary arterial hypertension (PAH) due to a failure of the trial to meet its primary endpoint of improvement in exercise capacity.
Gilead acquired cicletanine from Navitas Assets LLC in 2008 for a $10.9 million up-front payment and milestones. The drug is approved in some European countries for hypertension.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST